You are here:
20 April 2009
Consultation and Advisory Process
The World Bank, The GAVI Alliance and the AMC Donor Committee sought stakeholder input on the planning and design of the pilot AMC through expert groups, consultations, meetings and roundtables. The aim was to incorporate into the design of the AMC the recommendations of economists, global health experts, medical practitioners and scientists from developing and industrialized countries as well as manufacturers and civil society organizations.
01 April 2008
Economic Expert Group (EEG) Report
A report prepared by the Economic Expert Group convened by the GAVI Alliance to provide guidance to the pneumococcal AMC donors about key design decisions using new information available from industry consultations, demand forecasts and modeling of returns to industry under various demand and price scenarios.
11 March 2007
EEG Donor response
In May 2007, the AMC Donor Committee constituted an independent Economic Expert Group (EEG) to advise on the initial AMC design. This document is the donors' response to the EEG report.
10 July 2008
Implementation Working Group (IWG) Report
This report presents the group’s operational recommendations to inform donors’ decisions on AMC design and implementation. It is intended as an addendum to the EEG report, rather than a stand-alone document; therefore, readers will find a number of cross-references.
28 February 2006
Independent Expert Committee Membership
List of members of the Indepedent Expert Committee meeting in Paris, France held the 27-28 February 2008.
29 June 2007
Independent Expert Committee Recommendation for AMC Pilot
The Independent Expert Committee was convened to assess which of the six vaccines included in the Tremonti report would be most suitable for the pilot AMC.
IWG Joint Donor Statement
In February 2007, a collective US$1.5 billion for a pilot Advance Market Commitment (AMC) against pneumococcal disease was pledged by the Governments of Italy, the UK, Canada, Russia and Norway, and the Bill & Melinda Gates Foundation. The report recommends the terms on which the AMC will be offered to help developing countries buy new, more effective pneumococcal vaccines.
07 September 2006
Pilot proposal for the Advance Market Committment to demonstrate both the feasability of the AMC mechanism and its impact on accelerating vaccine development, production scale-up and introduction.
09 November 2006
Second Donor Working Group - Agenda London, November 2006
Agenda of the second meeting of the Technical Working Group in London on 9 November 2006.
Second Donor Working Group - Framework
Framework document for the pilot AMC for pneumococcal vaccines.
Second Donor Working Group - Participants London, November 2006
List of participants at the 2nd meeting of the AMC working group.
Second Donor Working Group - Summary London, November 2006
Summary of the second meeting of the Technical Working Group on AMC held in London on 9 November 2006.
31 March 2010
2009-2010 Pneumococcal AMC Annual Report
This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC since the signature of the legal agreements on 12 June 2009 up until 31 March 2010. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 13 April 2010.
01 April 2011
2010-2011 Pneumococcal AMC Annual Report
The 2011 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2010 to 31 March 2011.
01 June 2012
2011-2012 Pneumococcal AMC Annual Report
The 2012 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2011 to 31 March 2012. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.
29 April 2013
2012-2013 Pneumococcal AMC Annual Report
The 2013 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2012 to 31 March 2013. During this period a third tender was issued in response to the high level of country demand and eight countries introduced pneumococcal vaccines procured through the AMC, taking the total to 24 introductions by March 2013.
01 May 2014
2013-2014 Pneumococcal AMC Annual Report
This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC from 1 April 2013 to 31 March 2014. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 1 May 2014.
22 April 2015
2014-2015 Pneumococcal AMC Annual Report
The 2015 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2014 to 31 March 2015.
01 April 2016
2015 Pneumococcal AMC Annual Report
The 2015 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 January to 31 December 2015.
17 March 2008
All-Party Parlimentary Group on Pneumococcal Disease Report
This report summarises the results of the All-Party Parliamentary Group for Pneumococcal Disease Prevention in the Developing World (APPG) inquiry into pneumococcal disease in the developing world.
11 March 2005
Making markets for vaccines: Ideas to action
This report discusses the need to invest more in vaccines and the proposal of making a commitment in advance to buy vaccines if and when they are developed to create incentives for industry to increase investment in research and development.
08 February 2007
Pneumococcal Disease - The Human Face
Stories of three young children in Africa and Asia and their fight against pneumococcal disease.
Pneumococcal Disease Background
Streptococcus pneumoniae are bacteria that are frequently found in the upper respiratory tract of healthy children and adults. These bacteria, however, can also cause a range of infections – from relatively mild ear infections to fatal pneumonia, meningitis, and sepsis. Serious pneumococcal infections can occur throughout life, but children under two years old and the elderly are at highest risk.
02 December 2005
Tremonti Report to the G8 Finance Ministers
Background papers to the AMC providing the analysis underpinning Minister Giulio Tremonti's Report to the G8 Finance Ministers Advanced Market Commitments to Vaccines.
23 November 2012
Factsheet: Advance Market Commitment
Learn about Advance Market Commitment, including the pilot AMC for pneumococcal vaccines.
02 September 2016
Minutes from AMC eligibility determination meeting August 2016
Minutes from AMC eligibility determination meeting held on 9 August 2016.
24 April 2014
List of IAC members.
16 April 2010
Minutes from AMC eligibility determination meeting April 2010
Minutes from AMC eligibility determination meeting held in London, UK on 16 April 2010.
27 October 2009
IAC Selection Process
The selection process for Independent Assessment Committee (IAC) members is administered by the GAVI Alliance Secretariat, in its role as AMC Secretariat. Evaluation of candidates is conducted by a selection panel composed of five international leaders on global health issues.
11 December 2008
Minutes from December 2008 meeting
Minutes from the AMC Independent Assessment Committee (IAC) meeting on 11 December 2008.
03 November 2008
Minutes from November 2008 meeting
Minutes from the AMC Independent Assessment Committee (IAC) meeting on 3 November 2008.
07 March 2011
AMC deed of amendment and restatement
AMC deed of amendment and restatement relating to the Advance Market Commitment for pneumococcal vaccines offer agreement, IAC Charter & bylaws and procedures memorandum orginally dated 12 June 2009.
09 March 2011
AMC Legal Agreements: detailed list of modifications
List of modifications to the AMC legal agreements.
03 July 2009
Master Definitions Agreement
Master definitions schedule relating to the AMC for pneumococcal vaccines.
Revised AMC offer agreement
Offer agreement relating to the Advance Market Commitment for pneumococcal vaccines.
Revised AMC procedures memorandum
This Procedures Memorandum describes the procedures that would be applicable to any AMC.
11 March 2009
Revised Independent Assessment Committee charter and bylaws
The charter and bylaws of the Independent Assessment Committee (IAC).
29 October 2010
AMC Baseline Study
The AMC Baseline Study presents an innovative new approach to public health funding as a way of stimulating and accelerating the development and manufacture of vaccines for developing countries.
06 March 2013
AMC Process and Design Evaluation Appendix Feb 2013
The Advance Market Commitment for Pneumococcal Vaccines Process and Design Evaluation Appendix February 15, 2013 Contents Appendix ............................................................................................................................................ 2 Appendix I. Timelines and inputs to design pro
AMC Process and Design Evaluation Full Report
1 The Advance Market Commitment for Pneumococcal Vaccines Process and Design Evaluation Full Report February 15, 2013 Contents Preface ..................................................................................................................................................... 3 Acronyms and Abbreviations ......
AMC Process and Design Evaluation Mgt Response
Page 1 of 2 GAVI Secretariat Management Response to the Process and Design Evaluation of the Pilot Advance Market Commitment for Pneumococcal Vaccines Advance Market Commitments (AMCs) for vaccines aim to encourage the development and production of affordable vaccines tailored to the needs of developing countries. Foll
13 November 2008
Monitoring and Evaluability Study
The report was commissioned by the Monitoring & Evaluation Subgroup of the AMC Donor Committee in August 2007. The monitoring and evaluation proposals contained in this report have been designed to enable the effectiveness, efficiency and eventual impact of this pilot AMC to be measured over time and to assist with its effective management.
30 September 2011
Pneumococcal Advance Market Commitment: Lessons Learnt on Disease and Design Choices and Processes
This document describes early lessons learnt on the selection of a target disease, on core design choices, and on processes related to the pilot Advance Market Commitment (AMC) for pneumococcal vaccines. While ongoing monitoring and evaluations scheduled for the coming years will provide further information about the value of the Pneumo AMC, this document highlights some of the key lessons to date and aims to provide a starting point to inform discussions about the potential applications of the AMC concept to other vaccines or health and non-health interventions.
16 June 2010
Remaining AMC offer amount 2010
The official formal notification of the remaining AMC Offer Amount.
16 June 2011
Remaining AMC offer amount: June 2011
19 June 2012
Remaining AMC offer amount: June 2012
28 June 2013
Remaining AMC offer amount: June 2013
13 June 2014
Remaining AMC offer amount: June 2014
As of 12 June 2014, the Remaining AMC Offer Amount, corresponding to the AMC funds still available for allocation to industry, is: US $ 405,000,000.
15 June 2015
Remaining AMC offer amount: June 2015
The official formal notification of the remaining AMC Offer Amount
12 June 2016
Remaining AMC offer amount: June 2016
28 March 2014
Pneumo Strategic Demand Forecast - Version 8_0
Published 28 March 2014 PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast Version 8.0. This version 8.0 is issued in accordance with the GAVI Forecasting Standard Operating Procedure.
09 August 2012
Pneumo Strategic Demand Forecast - Version 5_0 – Published 13 August 2012
ACCELERATE VACCINE INTRODUCTION – PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast (Required Supply) Version 5.0 – updated in March 2012 Published – 13 August 2012 This version 5.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure.
11 March 2011
Pneumo SDF version 3.0 – published on 11 March 2011
This version 3.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure. The forecast captures all AMC‐eligible demand including countries that: introduce with GAVI support, graduate from GAVI support, and are fully self-financed.
07 August 2009
Pneumo SDF version 0.1 – published on 7 August 2009
This version 0.1 is issued in accordance with the AVI Forecasting Standard Operating Procedure that foresees the possibility for intermediate updates between official versions when changes in demand exceed predefined thresholds.
12 June 2009
Pneumo SDF version 0 – published on 12 June 2009
Pneumococcal vaccine strategic demand forecast corresponding to AMC required supply.
09 February 2007
Bill and Melinda Gates Foundation - Statement of Support
Statement from the Bill and Melinda Gates foundation announcing support for the pneumococcal AMC.
01 October 2009
Case Studies for Global Health - The World’s First Advance Market Commitment
A case study on the multi-sector effort to build a financing mechanism, the AMC, as an incentive to facilitate vaccine development.
IFPMA Press Release in support of AMC Launch
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) welcomes the public commitment made by the governments of Canada, Italy, Norway and the United Kingdom to fund the pilot Advance Market Commitment (AMC) to stimulate the development of new pneumococcal vaccines for the poorest countries.
Pope Address at Vaccine Project Launch
The address Pope Benedict XVI gave to the representatives of the Advance Market Commitment in Rome, Italy on 9 February 2007.
Remarks by Her Majesty Queen Rania of Jordan on the AMC Launch 2007
Remarks of Her Majesty Queen Rania Al-Abdullah on the announcement of Advanced Market Commitments of $1.5 billion in Rome, Italy on 9 February 2007.
01 September 2010
Serotype Replacement Note - Prepared by the IAC
The serotype replacement issue arises from extensive use of pneumococcal conjugate vaccine, which is expected to result in some increase of disease occurence due to serotypes not in the vaccine. This raises question whether the increases could reach a point where the benefit of the vaccine is lost, or the increases will be small relative to the decline in vaccine type disease.
30 November 2008
Codebook to assess whether a pneumococcal vaccine meets the Pneumococcal AMC Target Product Profile for regional vaccine serotype coverage.
18 December 2008
TPP Master Table
The master table of the target product profile (TPP), product specifications, relate to the public health impact and suitability of the product.
TPP Supplementary Information
Supplementary informational for the target product profile (TPP) including general information, vaccine characteristics relevant to the TPP, contributors and WHO policy documents.
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2017
modal window here